DNB Asset Management AS Sells 24,773 Shares of Boston Scientific Corporation $BSX

DNB Asset Management AS lowered its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 6.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 374,557 shares of the medical equipment provider’s stock after selling 24,773 shares during the period. DNB Asset Management AS’s holdings in Boston Scientific were worth $35,714,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Murphy & Mullick Capital Management Corp raised its holdings in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the second quarter valued at about $26,000. United Community Bank boosted its holdings in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares in the last quarter. Colonial Trust Co SC lifted its holdings in shares of Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 231 shares in the last quarter. Finally, Bangor Savings Bank grew its holdings in shares of Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $52.67 on Friday. Boston Scientific Corporation has a 52 week low of $52.52 and a 52 week high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The company’s fifty day moving average is $63.40 and its 200 day moving average is $81.79. The stock has a market cap of $78.27 billion, a PE ratio of 22.04, a PEG ratio of 0.98 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts anticipate that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. UBS Group lowered their price objective on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. Barclays cut their price target on Boston Scientific from $124.00 to $96.00 and set an “overweight” rating for the company in a report on Thursday, April 23rd. Raymond James Financial reaffirmed an “outperform” rating and set a $88.00 target price (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. Finally, Morgan Stanley decreased their price target on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $93.91.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.